India: India Moving Towards a TRIPS Compliant Patent Regime - Implications for the Pharmaceutical Industry

Last Updated: 11 August 2004
Article by Manisha Singh Nair


After independence in 1947, it took twenty-one years for India to enact a patent law. After joining WTO in 1995, India struggled through seven years of deliberations before it could amend its patent law to make it even partially TRIPS compliant. The last in the series of TRIPS compliance amendments in the national patent law was introduced in the Lok Sabha (the lower house of the Indian Parliament) on December 22, 2003. This Bill had been referred to the Department Related Parliamentary Standing Committee on Commerce. However, the dissolution of the Lok Sabha has necessitated the re-introduction of the Bill when the Parliament is convened after the general elections.

Introduction of product patents & other major changes

The proposed Patents (Amendment) Bill, 2003 aims to achieve the following:

  1. make the national law compliant with Art. 27 of the TRIPS agreement;
  2. provide for product patent protection for all categories of inventions;
  3. repeal the provisions concerning Exclusive Marketing Rights (EMRs);
  4. provide for a transitional provision to protect EMRs already granted;
  5. introduce provisions to give effect to the Doha Declaration on TRIPS and Public Health; and
  6. empower the IP Appellate Tribunal to adjudicate upon revocation of patents.

The proposed Bill will introduce product patents covering ‘all fields of technology’ ‘without discrimination as to the place of invention’, ‘the field of technology’ and irrespective of ‘whether products are imported or locally produced’. In all likelihood the product patent regime will change the way the pharmaceutical companies do business in India.

Exclusive Marketing Rights

At the time of joining the WTO, India did not have product patents for certain categories of inventions viz., food, drug and medicine. As a WTO member, India was under obligation to provide transitional protection for inventions in these fields.

In December 1994, India promulgated an Ordinance to amend the Patents Act to provide for a ‘Mail Box’ mechanism to receive product patent applications. However the, Government of India failed to substitute this Ordinance with a legislation passed by the Parliament. Consequently, a case was filed at the WTO by the US and the EU against India for not complying with the TRIPS obligation. India lost the case at the Dispute Settlement Panel of the WTO. India preferred an appeal against the decision of the Panel to the Appellate Body. The Appellate Body also decided the case against India by December 1997 and gave fifteen months time till April 1999 to comply with the TRIPS obligation respecting the transitional protection. The controversy ended when India amended its Patent law in March 1999 and introduced a new chapter IVA dealing with Exclusive Marketing Rights. The Patent Rules 1972 was also amended in June 1999 to introduce Chapter IIIA to provide for filing and prosecution mechanism for Exclusive Marketing Rights.

EMR has been a key topic for deliberations in the Indian pharmaceutical business circles in the recent past. Very few companies have been able to meet with the requirements set under the amended patents law. The details of the EMRs granted so far as well as EMRs applied for are as follows:




Title of the EMR/Patent Application and related Drug Product

Brand Name


Glaxosmithkline Beecham

Rosiglitazone (Novel compounds)


EMR rejected

Glaxosmithkline Beecham

Novel compounds (name of drug product not available)

Not known

EMR Rejected


Imatinib mesylate


EMR granted (the first EMR in India)




EMR granted

United Phosphorus

Combination of Carbedazim & Macozeb


EMR granted (first EMR of an Indian company)

Nicolas Piramal



EMR Application Pending


Saquinavir mesylate


EMR rejected




EMR Application Pending

Astra Zeneca



EMR Application Pending

Astra Zenca



EMR Application Pending


Pharmaceutical compositions containing Benzoquinolizines

Not known

EMR Application Pending

Schering Plough

Biotech – interferon alpha

Not known

EMR Application Pending

Bristol-Myers Squibb



EMR Application Pending




EMR Application Pending


Zoledronic acid


EMR Application Pending


Once-a-day oral controlled release form


EMR Application Rejected

Eli Lilly

Tetracyclic derivatives, process for preparation and use thereof

Not known

EMR Application Pending

Clause 21 of the proposed amendment bill omits Chapter IV A of the Patents Act, 1970 that deals with Exclusive Marketing Rights. A new set of provisions has been proposed in the Bill to protect the EMRs already granted. The pending applications for EMRs will be treated as request for examination under Section 11B. All EMR related infringement suits pending before the courts will be treated as patent infringement suits once the new law takes effect.

Compulsory licensing – the balancing act

The availability of medicines at affordable prices is a key health concern. It was this key concern that compelled the Government of India to augment the reach and scope of compulsory licensing in the Patents Act. The Patents Act, 1970 contained detailed provisions respecting compulsory licenses. But these provisions were never put to use. However, in view of the introduction of product patents, the Government of India has made compulsory licensing provisions further stringent. Any interested person can apply to the Controller of Patents seeking a compulsory license if the ‘reasonable requirements’ of the public with respect to the patented invention is not satisfied, or the patented invention is not available to the public at reasonably affordable price, or when the patented invention is not worked in the territory of India. An attempt has been made to explain the meaning of an otherwise vague expression ‘reasonable requirements’ in Section 84(7). However these explanations do not clarify clearly the situations in which an interested person can invoke compulsory licensing provisions, leaving the expression ‘reasonable requirements’ more or less ambiguous.

The Patents (Amendment) Bill, 2003 introduces a new section namely 92A in the principal Act relating to the grant of compulsory licenses for manufacture and export of patented pharmaceutical products in certain exceptional circumstances. This amendment is intended to implement Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. According to this provision compulsory license will be granted to manufacture and export patented pharmaceutical products to a country, having insufficient or no manufacturing capacity in respect of that product, provided the applicant has obtained a compulsory license in that country for that product.

The provisions on compulsory licensing will have a bearing on the way the multinational pharmaceutical companies propose to do business in India after January 1, 2005. Making drugs available at affordable prices will be a key issue for multinational pharmaceutical companies. Those who do not have their own manufacturing units will need to enter into licensing arrangements with local counterparts. Indian pharmaceutical companies are likely to make use of the ambiguity in the provisions relating compulsory licenses. The sub-clauses (a) through to (e) of Clause (7) of Section 84 are adequately ambiguous, giving the Indian companies the scope to use it to their advantage.

Parties aggrieved by the grant as well as the refusal of EMRs have filed cases at the High Court setting the scene for a large number of potential product patent litigations.


The scene has been set in India for an interesting era in the national patent system. The decade ahead will witness a vibrant phase of dialectics that will hopefully contribute to the emergence of a patent system capable of absorbing the often conflicting interests of the stakeholders – the Indian and the multinational pharmaceutical companies, the patent administration system and judiciary and the people of India.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.